
1 
This Order may be cited as the General Pharmaceutical Council (Amendment) Rules Order of Council 2022 and comes into force on 6th October 2022.
2 
Their Lordships, having taken the Rules as set out in the Schedule to this Order into consideration, are pleased to, and do, approve them.
Richard Tilbrook
Clerk of the Privy Council

SCHEDULE
The General Pharmaceutical Council makes these Rules in exercise of the powers conferred by articles 61(1), (2)(a) and (6)(b) and 66(1) of the Pharmacy Order 2010.
In accordance with article 66(3) of that Order the Pharmaceutical General Council has consulted such persons or organisations as it considered appropriate.

1 
These Rules may be cited as the General Pharmaceutical Council (Amendment) Rules 2022 and come into force on 6thOctober 2022.
2 

(1) The General Pharmaceutical Council (Appeals Committee) Rules 2010 are amended as follows.
(2) In rule 2 (interpretation)—
(a) after the definition of “appellant” insert—“
 “attend” means—
(a) to be physically present at a meeting or hearing, or,
(b) to be present at a meeting or hearing by teleconference or video link;”; and
(b) after the definition of “parties” insert—“
 “present” includes being in a meeting or hearing by teleconference or video link and “presence” is to be construed accordingly;”.
(3) After rule 2 insert—“
2A. 
At the discretion of the chair, meetings or hearings of the Committee arranged under these Rules may be conducted by teleconference or video link.”.
(4) In rule 6 (notice of hearing), for sub-paragraph (a), substitute—“
(a) state—
(i) the date, time and venue of the hearing, or
(ii) when the hearing is to be conducted by teleconference or video link, the date and time of the hearing and instructions on how to access the hearing;”.
(5) After rule 16(4) (attendance of the public at hearings), insert—“
(5) Reference to a hearing under this rule includes hearings conducted by teleconference or video link.”.
3 

(1) The General Pharmaceutical Council (Fitness to Practise and Disqualification etc) Rules 2010 are amended as follows.
(2) In rule 2 (interpretation)—
(a) after the definition of “applicant concerned” insert—“
 “attend” means—
(a) to be physically present at a meeting or hearing, or,
(b) to be present at a meeting or hearing by teleconference or video link;”; and
(b) after the definition of “prescribed fee” insert—“
 “present” includes being present at a meeting or hearing by teleconference or video link, except in the phrase “present their case”, and “presence” is to be construed accordingly;” and
(3) After rule 2 (interpretation), insert—“
2A. 
At the discretion of the chair, meetings and hearings of the Committee arranged under these rules may be conducted by teleconference or video link.”.
(4) In rule 16 (notices of hearing other than interim order hearings), for sub-paragraph 2(a), substitute—“
(a) state—
(i) the date, time and venue of the hearing, or
(ii) when the hearing is to be conducted by teleconference or video link the date and time of the hearing and instructions on how to access the hearing;”.
(5) In rule 17 (interim order notices and court referrals), for sub-paragraph 2(a), substitute—“
(a) state—
(i) the date, time and venue of the hearing, or
(ii) when the hearing is to be conducted by teleconference or video link, the date and time of the hearing and instructions on how to access the hearing;”.
(6) After rule 39(4) (attendance of the public at hearings), insert—“
(5) Reference to a hearing under this rule includes hearings conducted by teleconference or video link.”.
Given under the common seal of the General Pharmaceutical Council this 12th day of May 2022.
Gisela Abbam
Chair of the Council

Duncan Rudkin
Chief Executive and Registrar
